Effect of preferential cyclooxygenase-2 (cox-2) inhibitor against l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (mptp)-induced striatal lesions in rats: Behavioral, biochemical and histological evidences

Indian Journal of Experimental Biology

Volumn 48, Issue 6, 2010, Pages 577-585

  Gupta, Amit ^a   Dhir, Ashish ^a   Kumar, Anil ^a   Kulkarni, S K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

1 methyl 4 phenyl l,2,3,6 tertahydropyridine; Cyclooxygenase; Neuroprotection; Nimesulide; Oxidative stress; Parkinson's disease; References

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIOXIDANT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NEUROPROTECTIVE AGENT; NEUROTOXIN; NIMESULIDE; SULFONAMIDE;

ANIMAL; ARTICLE; CHEMISTRY; CORPUS STRIATUM; DRUG EFFECT; ENZYMOLOGY; INTOXICATION; LIPID PEROXIDATION; MALE; METABOLISM; MITOCHONDRION; MOTOR ACTIVITY; OXIDATIVE STRESS; PATHOLOGY; RAT; WISTAR RAT; DRUG EFFECTS; MPTP POISONING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIOXIDANTS; CORPUS STRIATUM; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; LIPID PEROXIDATION; MALE; MITOCHONDRIA; MOTOR ACTIVITY; MPTP POISONING; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXIDATIVE STRESS; RATS; RATS, WISTAR; SULFONAMIDES;

RATTUS;

EID: 77954286433     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Montastruc JL, Rascol O & Senard JM, New directions in the drug treatment of Parkinson's disease, Drugs Aging, 9 (1996) 169.
2. Bartels AL & Leenders KL, Neuroinflammation in the pathophysiology of Parkinson's disease: Evidence from animal models to human in vivo studies with [11C]-PK11195 PET, Mov Disord, 22 (2007) 1852.
3. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V & Przedborski S, Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration, Proc Natl Acad Sci USA, 100 (2003) 5473.
4. Monahan AJ, Warren M & Carvey PM. Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis, Cell Transplant, 17 (2008) 363.
5. Smeyne RJ & Jackson-Lewis V, The MPTP model of Parkinson's disease, Brain Res Mol Brain Res, 134 (2005) 57.
6. Garcia E, Limon D, Perez-De La Cruz V, Giordano M, Diaz-Muñoz M, Maldonado PD, Herrera-Mundo MN, Pedraza-Chaverri J, & Santamaria A, Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine, Free Radic Res, 42 (2008) 892.
7. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE & Pahan K, Selective inhibition of NF-kappab activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease, Proc Nad Acad Sci USA, 104 (2007) 18754.
8. Vroon A, Drukarch B, Bol JG, Cras P, Breve JJ, Allan SM, Relton JK, Hoogland PV & VanDam AM, Neuroinflammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: Microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb, Exp Gerontol, 42 (2007) 762.
9. Yokoyama H, Kuroiwa H, Yano R & Araki T, Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease, Neurol Sci, 29 (2008) 293.
10. Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debr P, Agid Y, Dugas B & Hirsch E, FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-α in glial cells, JNeurosci, 19 (1999) 3440.
11. Kim YS & Joh TH, Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease, Exp Mol Med, 38 (2006) 333.
12. Minghetti L, Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases, J Neuropathol Exp Neurol, 63(2004)901.
13. Aguirre JA, Leo G, Cueto R, Andbjer B, Naylor A, Medhurst AD, Agnati LF & Fuxe K, The novel cyclooxygenase-2 inhibitor GW637185x protects against l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity, Neuroreport, 19 (2008) 657.
14. Teismann P & Ferger B, Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease, Synapse, 39 (2001) 167.
15. Akula KK, Dhir A & Kulkarni SK, Rofecoxib, a selective cyclooxygenase-2(COX-2)inhibitorincreases pentylenetetrazol seizure threshold in mice: Possible involvement of adenosinergic mechanism, Epilepsy Res, 78 (2008) 60.
16. Dhir A, Naidu PS & Kulkarni SK, Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice, Seizure, 16 (2007)691.
17. Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, Ali SF, Langenbach R & Hong JS, Cyclooxygenase-2-deficient mice are resistant to l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra, Neurosci Lett, 329 (2002) 354.
18. Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F & Venegoni M, Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs, BMJ, 327 (2003) 18.
19. Wang Y, Deng XL, Xiao XH & Yuan BX, A non-steroidal anti-inflammatory agent provides significant protection during focal ischemic stroke with decreased expression of matrix metalloproteinases, Curr Neurovasc Res, 4 (2007) 176.
20. Paxinos G, Watson C, Pennisi M & Topple A, Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight, J Neurosci Methods, 13 (1985) 139.
21. Gupta A, Dhir A, Kumar A & Kulkarni SK, Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats, Pharmacol Biochem Behav, 94 (2009) 219.
22. Ohkawa H, Ohishi N & Yagi K, Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction, Anal Biochem, 95(1979)351.
23. Ellman GL, Tissue sulfhydryl groups, Arch Biochem Biophys, 82 (1959) 70.
24. Drechsel DA, Liang LP & Patel M, l-methyl-4-phenylpyridinium-induced alterations of glutathione status in immortalized rat dopaminergic neurons, Toxicol Appl Pharmacol, 220 (2007) 341.
25. Kono Y, Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase, Arch Biochem Biophys, 186 (1978) 189.
26. Bird JE, Milhoam K, Wilson CB, Young SG, Mundy CA, Parthasarathy S & Blanty RC, Ischemic acute renal failure and antioxidant therapy in rats, J Clin Invest, 31 (1988) 1630.
27. Raghavendra V, Agrewala JN & Kulkarni SK, Melatonin reversal of lipopolysacharides-induced thermal and behavioral hyperalgesia in mice, Eur J Pharmacol, 395 (2000) 15.
28. Lowry OH, Rosenbrough NJ, Farr AL & Randall RJ, Protein measurement with Folin-phenol reagent, J Biol Chem, 193 (1951)265.
29. Berman SB & Hastings TG, Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease, J Neurochem, 73 (1999) 1127.
30. King TE & Howard RL, Preparations and properties of soluble NADH dehydrogenases from cardiac muscle, Methods Enzymol, 10 (1967) 275.
31. Mosmann T, Rapid colorimetric assay for cellular growth survival: application to proliferation and cytotoxicity assays, J Immunol Methods, 65 (1983) 55.
32. Humanson GL, Animal tissue techniques (WH Freeman, San Franscisco) 1962, 126.
33. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, Laurie C & Gendelman HE, Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease, Clin Neurosci Res, 6 (2006) 261.
34. Watanabe Y, Kato H & Araki T, Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease, Metab Brain Dis, 23 (2008)51.
35. Slivka A & Cohen G, Hydroxyl radical attack on dopamine, JBiol Chem, 260 (1985) 15466.
36. Hastings TG, Enzymatic oxidation of dopamine: The role of prostaglandin H synthase, J Neurochem, 64 (1995) 919.
37. Gerlach M, Blum-Degen D, Lan J & Riederer P, Nitric oxide in the pathogenesis of Parkinson's disease, Adv Neurol, 80 (1999)239.
38. Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL & Bing G, Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease, J Neuroinflammation, 3 (2006) 6.
39. Spina MB & Cohen G, Dopamine turnover and glutathione oxidation: implications for Parkinson disease, Proc Natl AcadSci USA, 86 (1989) 1398.
40. Spina MB & Cohen G, Hydrogen peroxide production in dopamine neurons, Basic Life Sci, 49 (1988) 1011.
41. Adams JD Jr, Lauterburg BH & Mitchell JR, Plasma glutathione and glutathione disulfide in the rat: regulation and response to oxidative stress, J Pharmacol Exp Ther, 227 (1983)749.
42. Ferger B, Spratt C, Teismann P, Seitz G & Kuschinsky K, Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo, Eur J Pharmacol, 360 (1998) 155.
43. Penn MS, The role of leukocyte-generated oxidants in left ventricular remodeling, Am J Cardiol, 101 (2008) 30.
44. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV & Greenamyre JT, Chronic systemic pesticide exposure reproduces features of Parkinson's disease, Nat Neurosci, 3 (2000) 1301.